Search Bar & Filters
Found 458 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.
Actively Recruiting
Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for extensive-stage small cell lung cancer ES-SCLC, a type of lung cancer that has spread widely within the lungs or to other parts of the body. This study evaluates the combination of two investigational drugs, gocatamig and ifinatamab deruxtecan I-DXd, alongside standard chemotherapy and immunotherapy treatments. The research aims to understand the safety and tolerability of these combined therapies and whether they can reduce or eliminate cancer in participants. Participants in the trial may receive different treatment regimens depending on their prior therapy history. Some will receive gocatamig and I-DXd together in maintenance after standard chemotherapy and immunotherapy, while others will receive these drugs during both induction and maintenance phases. Additional groups will receive combinations including gocatamig, I-DXd, atezolizumab, carboplatin, and etoposide in varying sequences. Treatments are delivered intravenously, and participants continue until disease progression or other criteria require stopping. During the study, participants will have regular assessments including imaging to measure tumor response, safety monitoring for adverse events, and laboratory tests to understand drug levels and immune reactions. Researchers will track side effects, dose-limiting toxicities, and treatment discontinuations over a period of up to about 58 months. The main outcomes include tumor response and safety, with ongoing evaluation of disease control, survival, and drug exposure throughout the study duration.
Actively Recruiting
Researchers are investigating new treatment options for people with precursor B-cell Acute Lymphoblastic Leukemia B-ALL that has either returned after treatment relapsed or stopped responding to current therapies refractory. This study has two parts the first part focuses on finding the safest and most effective dose of the study drug MK-1045, while the second part aims to understand how well MK-1045 works to treat B-ALL. Participants receive MK-1045 through an intravenous infusion once a week. Adults in the dose escalation phase will be given doses ranging from 600 micrograms to 120,000 micrograms, while pediatric participants receive doses from 320 micrograms to 60,000 micrograms, adjusted based on their weight. Treatment cycles last 4 weeks, starting with two cycles of induction therapy, followed by consolidation and maintenance treatments separated by breaks depending on response and tolerance. During the study, researchers monitor participants closely with various tests to assess safety, drug levels in the blood, immune cell changes, and treatment responses. These include tracking adverse events, remission rates, and survival outcomes over time. The study involves up to 24 months of follow-up to evaluate both the safety and effectiveness of MK-1045 in treating relapsed or refractory B-ALL.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating the SHR-A1811 combination in patients with HER2-positive locally advanced or metastatic biliary tract cancer. This open, multicenter Phase II clinical trial aims to assess the effectiveness and safety of this treatment combination in this specific patient group. The study is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and focuses on an important cancer subtype with limited treatment options. Participants will receive the SHR-A1811 combination, which includes the drugs SHR-A1811, SHR-1316, and SHR-8068. The study does not use placebo or blinding, and all enrolled patients receive the experimental treatment. The trial runs from screening through completion over an average period of three years, during which the treatments impact on the cancer will be closely monitored. During the study, participants will undergo regular assessments to measure the objective response rate, duration of response, disease control rate, progression-free survival, overall survival, and any adverse events. These evaluations will involve clinical examinations and monitoring by investigators. The total participation time includes screening and follow-up over about three years to collect comprehensive safety and efficacy data.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SPH5030 tablets in adults with Her2-positive or Her2-mutated biliary tract or colorectal cancer. This phase II clinical study focuses on patients with metastatic, unresectable, or advanced forms of these cancers who have specific genetic markers and meet certain health criteria. The study is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and aims to better understand treatment outcomes in this group. Participants will receive SPH5030 tablets orally once daily at a dose of 600 mg. The study is open-label and single-arm, meaning all participants receive the same treatment without a placebo group. The treatment period and follow-up span approximately two years, during which multiple outcome measures will be assessed. During the study, participants will undergo regular evaluations to monitor tumor response, duration of remission, disease control, progression-free survival, overall survival, and any adverse events related to treatment. Researchers will also assess safety through clinical and laboratory tests. The total involvement for each participant is about two years, allowing for detailed observation of treatment effects and tolerability.
Actively Recruiting
Researchers are conducting an open-label, multicenter Phase II clinical trial in adults with advanced breast cancer to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the drug SYS6023 in combination with other agents. The study focuses on patients with unresectable locally advanced or metastatic breast cancer who have progressed on or are intolerant to prior treatments. This trial is sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. and aims to gather important information about these combination therapies to better understand their effects. Participants will receive SYS6023, a novel antibody-drug conjugate targeting HER3, combined with either HB1901 or KN026, an antibody targeting HER2. Both drugs are administered via intravenous infusion every three weeks. Treatment cycles continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapies, withdrawal of consent, loss to follow-up, or death. The study includes a safety run-in period and a cohort expansion phase to assess dose levels and responses. Throughout the trial, participants will be closely monitored with assessments including tumor marker expression, plasma drug concentrations, and evaluations of disease control, response duration, progression-free survival, and overall survival. Safety is tracked by documenting adverse events and dose-limiting toxicities from baseline through up to three years after the last dose. Participants are expected to undergo regular laboratory tests and imaging to measure efficacy and safety outcomes during the treatment period and follow-up.
1-10 of 458
1